Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pacritinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 18/20 | 0.89 |
| ▸ | FLT3 known ✓ | P36888 | 15/20 | 0.89 |
| ▸ | IRAK1 known ✓ | P51617 | 1/20 | 0.89 |
| ▸ | ACVR1 known ✓ | Q04771 | 1/20 | 0.89 |
| ▸ | TYK2 | P29597 | 13/20 | 0.89 |
| ▸ | CDK2 | P24941 | 11/20 | 0.89 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.89 |
| ▸ | JAK1 | P23458 | 10/20 | 0.89 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.89 |
| ▸ | JAK3 | P52333 | 9/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.89 |
| ▸ | GAK | O14976 | 1/20 | 0.89 |
| ▸ | STK16 | O75716 | 1/20 | 0.89 |
| ▸ | STK10 | O94804 | 1/20 | 0.89 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.89 |
| ▸ | PRKCB | P05771 | 1/20 | 0.89 |
| ▸ | LCK | P06239 | 1/20 | 0.89 |
| ▸ | CSF1R | P07333 | 1/20 | 0.89 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.89 |
| ▸ | NQO2 | P16083 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pacritinib SCHEMBL31537559 | 0.94 | JAK2 (1.00) | JAK2FLT3TYK2CDK2CCNA2 | |
| Pacritinib SCHEMBL29395340 | 0.94 | JAK2 (1.00) | JAK2FLT3TYK2CDK2CCNA2 | |
| Pacritinib SCHEMBL30802892 | 0.94 | JAK2 (1.00) | JAK2FLT3TYK2CDK2CCNA2 | |
| Pacritinib SCHEMBL26687652 | 0.94 | JAK2 (1.00) | JAK2FLT3TYK2CDK2CCNA2 | |
| Pacritinib SCHEMBL1108221 | 0.94 | JAK2 (1.00) | JAK2FLT3TYK2CDK2CCNA2 | |
| Pacritinib SCHEMBL2537450 | 0.93 | JAK2 (0.98) | JAK2FLT3TYK2CDK2CCNA2 | |
| SCHEMBL1108252 | 0.90 | JAK2 (0.92) | JAK2FLT3TYK2CDK2CCNA2 | |
| Pacritinib SCHEMBL30277987 | 0.90 | JAK2 (0.83) | JAK2FLT3TYK2CDK2CCNA2 | |
| Pacritinib SCHEMBL2336009 | 0.90 | JAK2 (0.83) | JAK2FLT3TYK2CDK2CCNA2 | |
| SCHEMBL20322432 | 0.89 | JAK2 (0.89) | JAK2FLT3TYK2CDK2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376500-B1 | 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE MALEATE SALT | CTI BIOPHARMA CORP (US) | 2015-02-25 | — | — | EP | disclosed |
| US-20110263616-A1 | 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE MALEATE SALT | S*BIO PTE LTD. (SG) | 2011-10-27 | — | — | US | disclosed |
| EP-2376500-A1 | 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE MALEATE SALT | S*BIO Pte Ltd (SG) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010068182-A1 | 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE MALEATE SALT | S*BIO PTE LTD (SG) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263616-A1 | 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE MALEATE SALT | IL17A, SLC10A1, PKD1 | JAK2 505/4885FLT3 3153/4885IRAK1 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.